• Goldman Sachs (NYSE:GS) reported third quarter earnings of $5.25 a share, versus Zacks estimates of $4.14 a share, as revenues rose to $12.37 billion from $11.02 billion

• Citigroup (NYSE:C) reported a 27 cent per share loss for the quarter, inline with Zacks estimates, on revenues of $20.4 billion

• Baxter International (NYSE:BAX) reported third quarter earnings of 98 cents a share, one cent above Zacks estimates, on revenues of $3.15 billion

• Research in Motion (NASDAQ:RIMM) is due to launch its new version of a touchscreen Blackberry, the Storm2 today

• Singapore's Oversea-Chinese Banking Group agreed to pay ING Group (NYSE:ING) $1.46 billion for its private banking operations in Asia

• According to Gartner data Acer overtook Dell (NASDAQ:DELL) as the number 2 PC computer brand by market share, with 15.4% of the global market, versus Dell's 12.8% and Hewlett-Packard's (NYSE:HPQ) 20%

• Anheuser-Busch InBev (NYSE:BUD) passed its $7 billion divestment goal to help repay its $52 billion Anheuser-Busch takeover, agreeing

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Wednesday October 7, 2009

DrStockPick.com Stock Report!

RPRX, PWRM, WYN, CSRH, BX, CVAT, DELL, AQNM, IBM

**************************************************************

RPRX, Repros Therapeutics Inc.

RPRX focuses on the development of oral small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.

Secondary hypogonadism is a deficiency state in which the male hormone testosterone goes below the normal range, even in aging men, due to inadequate stimulation of the testes by the pituitary.

The results from an exploratory, efficacy and safety study of RPRX’s oral investigational product, enclomiphene citrate (Androxal®), in men with secondary hypogonadism who were receiving testosterone replacement treatment shows that RPRX’s

...

Monmouth Real Estate Investment Corp. reported funds from operations (FFO) of $3.692 million, or $0.15 per share, for its third fiscal quarter of 2009, ending 6/30/2009. This brings its nine months FFO to $11.89 million or $0.48 per share, excluding non-cash impairment and other one-time charges.

Other highlights in the quarter include:

• An ending cash balance of $8.0 million • Occupancy rate of 96% • Average lease maturity of approximately 5 years

Eugene W. Landy, the President of Monmouth Real Estate Investment Corporation, said, “MREIC continues to perform well despite weakness in the overall economy. By investing in net-leased industrials on long-term leases to investment-grade tenants, our income streams have proven to be resilient.

The company also paid a common stock dividend of $0.15 in the quarter, bringing its annual rate to $0.60. Monmouth Real Estate Investment Corporation has a yield of over 9% based on its recent closing price of $6.42.

Monmouth

...

For Immediate Release

Chicago, IL – July 30, 2009 – Zacks Equity Research highlights Companhia de Bebidas das Americas or AmBev (ABV) as the Bull of the Day and First Advantage Corporation (FADV) the Bear of the Day. In addition, Zacks Equity Research provides analysis on Unisys (UIS), IBM (IBM) and Computer Sciences Corporation (CSC).

Full analysis of all these stocks is available at http://at.zacks.com/?id=2676

Here is a synopsis of all five stocks:

Bull of the Day:

We are maintaining our Buy recommendation on Companhia de Bebidas das Americas or AmBev (ABV). The company posted good results for the first quarter of 2009 with excellent results in the key Brazilian market.

InBev's acquisition of Anheuser-Busch was positive for the company as it creates huge synergies. Despite the difficult economic environment throughout the world due to the global credit crunch, the company,

...

We are maintaining our Buy recommendation on Companhia de Bebidas das Americas, or AmBev (ABV). The company posted good results for the first quarter of 2009 with excellent results in the key Brazilian market.

InBev's acquisition of Anheuser-Busch was positive for the company as it creates huge synergies. Despite the difficult economic environment throughout the world due to the global credit crunch, the company, which is focusing on low cost, daily use products, is not tied directly to the international economic cycle.

Also, a more relaxed monetary policy in Brazil is very positive for the company. Our target price is $79.50 per share.Zacks Investment Research

Pepsico and AmBev - a Cola and a Beer, Together?

Tony Daltorio, The Investment U Research Team

According to a recent research study for the Financial Times prepared by the consulting firm Wolff Olins, the world’s next top brands are set to rise in the east. A strategist at Wolff Olins, Melanie McShane, stated that “It used to be possible to be a global brand by dominating the US market. That’s changing rapidly. Now you have to be number one in Asia.”

The findings of the Wolff Olins research echo research by the US-based consulting firm, Bain & Co. Their research estimated that one-third of the FT Global 500 companies could come from emerging markets by 2015 thanks to what it calls a “seismic shift” away from developed markets.

A partner with Bain & Co. said that established western consumer

...

Molson Coors Brewing Co. (TAP) boosted its quarterly dividend today by 20% to 24 cents per share.

The brewer said it's in a strong position to increase cash returns to shareholders while maintaining the financial flexibility to exploit growth opportunities.

Molson Coors also stated that it has bolstered its financial strength over the past 4 years by building brands, controlling costs, paying down debt and boosting cash flow. The company was formed by the merger of Molson Co. and Adolph Coors in 2005.

Last week, the owner of Blue Moon and Keystone brands reported first-quarter earnings of 53 cents per share, which came in well ahead of the 32-cent consensus estimate.

Molson Coors and SABMiller Plc. combined their US operations last year in an effort to challenge archrival Anheuser-Busch.

Shares of the Zacks #3 Rank ("Hold") company were rather steady today on lower-than-usual volume of about 1.1 million,

...

Anheuser-Busch InBev, Tsingtao Beer's second-largest single shareholder, has announced that it will sell 91,641,342 H shares in Tsingtao Beer for HKD19.83 per share to Chen Fashu, chairman of the Fujian-based New Huadu Industrial Group. According to a representative from the public relations department of Anheuser-Busch InBev China the transaction, which has a total value of USD235 [...]

For Immediate Release

Chicago, IL - May 13, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Vale do Rio Doce (VALE), Cytori Therapeutics (CYTX), Allegheny Energy Inc. (AYE), AmBev (ABV) and The PMI Group, Inc. (PMI).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579.

Here are highlights from Tuesday's Analyst Blog:

VALE Now More China-Dependent

Some days ago, Vale do Rio Doce (VALE) posted weaker-than-expected first quarter 2009 results. The numbers showed a remarkable contrast between the actual results of the company and the great performance the stock has been showing

...

We are maintaining our Buy recommendation on Companhia de Bebidas das Americas, or AmBev (ABV). The company posted good results for the first quarter of 2009 with excellent results in the key Brazilian market. InBev's acquisition of Anheuser-Busch was positive for the company as it creates huge synergies.Despite the difficult economic environment throughout the world due to the global credit crunch, the company, which is focusing on low cost, daily use products, is not tied directly to the international economic cycle. Also, a more relaxed monetary policy in Brazil is very positive for the company.In our opinion, ABV's valuation should be between 20.0x to 21x EPS estimate. Our target price is $67.50 according to our detailed DCF [discounted cash flow] model, representing a P/E between 17x and 17.5x our 2009 earnings estimates -- an acceptable premium over the industry mean, considering the above-average growth ...